irinotecan has been researched along with sar 020106 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Addison, G; Aherne, GW; Box, G; Boxall, K; Burns, S; Cherry, M; Cheung, KM; Collins, I; de Haven Brandon, A; Eccles, SA; Ellard, J; Eve, P; Fisher, M; Garrett, MD; Hayes, A; Klair, S; Matthews, TP; Piton, N; Proisy, N; Raynaud, FI; Reader, JC; Scanlon, J; Taylor, S; Valenti, M; van Montfort, RL; Walton, MI; Westwood, IM; Williams, DH | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; de Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Lainchbury, M; Matthews, TP; McHardy, T; Raynaud, FI; Reader, JC; Valenti, MR; Walton, MI | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, A; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Raynaud, FI; Reader, JC; Valenti, M; Walton, MI; Williams, DH | 1 |
3 other study(ies) available for irinotecan and sar 020106
| Article | Year |
|---|---|
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Biological Availability; Cell Line, Tumor; Checkpoint Kinase 1; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyridines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2011 |
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Checkpoint Kinase 1; Child; Colonic Neoplasms; DNA Damage; Drug Design; Humans; Mice; Mice, Nude; Mice, Transgenic; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Synergism; G2 Phase; Gemcitabine; Humans; Irinotecan; Isoquinolines; Mice; Mice, Nude; Mutagens; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2010 |